Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epiretinal brachytherapy for wet AMD gets NICE thumbs down

This article was originally published in Clinica

Executive Summary

Epiretinal brachytherapy for treating wet age-related macular degeneration (AMD) should only be used in the context of research, the UK’s National Institute for Health and Clinical Excellence (NICE) has said. In guidance issued today under its interventional procedures programme, NICE cited safety concerns raised by the technique and the need for better evidence on its effectiveness.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel